Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple-negative breast cancer

Cancer Research

Volumn 76, Issue 7, 2016, Pages 2013-2024

  Merino, Vanessa F ^a   Nguyen, Nguyen ^a   Jin, Kideok ^a   Sadik, Helen ^a   Cho, Soonweng ^a   Korangath, Preethi ^a   Han, Liangfeng ^a   Foster, Yolanda M N ^a   Zhou, Xian C ^a   Zhang, Zhe ^a   Connolly, RoisinM ^a   Stearns, Vered ^a   Ali, SyedZ ^a   Adams, Christina ^a   Chen, Qian ^a   Pan, Duojia ^a   Huso, David L ^a   Ordentlich, Peter ^b   Brodie, Angela ^c   Sukumar, Saraswati ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Syndax Pharmaceuticals   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ENTINOSTAT; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; RETINOIC ACID; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPIGENETICS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR REGRESSION; TUMOR XENOGRAFT; GENETIC EPIGENESIS; GENETICS; METABOLISM; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; EPIGENESIS, GENETIC; HUMANS; NEOPLASTIC STEM CELLS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84963784240     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1619     Document Type: Article

References (36)

1. Davis SL, Eckhardt SG, Tentler JJ, Diamond JR. Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol 2014;6:88-100.
2. Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 2009;8:3297-302.
3. Bhat-Nakshatri P, Goswami CP, Badve S, Sledge GW Jr, Nakshatri H. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci Rep 2013;3:2530.
4. Connolly RM, Nguyen NK, Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res 2013;19:1651-9.
5. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 2011;6:345-64.
6. Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 2000;19:1556-63.
7. Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH, et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999;59:5464-70.
8. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014;124:30-9.
9. Connolly R, Stearns V. Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia 2012;17:191-204.
10. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009;101:1044-50.
11. Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007;13:3605-10.
12. Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, et al. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 2012;106:77-84.
13. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-73.
14. Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 2005;19:1740-51.
15. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-70.
16. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 2004;101:4966-71.
17. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and apredictor ofpoor clinical outcome. Cell Stem Cell 2007;1:555-67.
18. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 2002;62:2455-61.
19. Kumar S, Duester G. SnapShot: retinoic acid signaling. Cell 2011;147:1422-22 e1.
20. Liu T, Bohlken A, Kuljaca S, Lee M, Nguyen T, Smith S, et al. The retinoid anticancer signal: mechanisms of target gene regulation. Br J Cancer 2005;93:310-8.
21. Chen H, Zhang H, Lee J, Liang X, Wu X, Zhu T, et al. HOXA5 acts directly downstream of retinoic acid receptor beta and contributes to retinoic acidinduced apoptosis and growth inhibition. Cancer Res 2007;67:8007-13.
22. Chen MC, Chen CH, Chuang HC, Kulp SK, Teng CM, Chen CS. Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIalpha degradation in hepatocellular carcinoma cells. Hepatology 2011;53:148-59.
23. McNamara S, Wang H, Hanna N, Miller WH Jr. Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance. Molecular and Cellular Biology 2008;28:2066-77.
24. Papi A, Guarnieri T, Storci G, Santini D, Ceccarelli C, Taffurelli M, et al. Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ 2012;19:1208-19.
25. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
26. Cheong HS, Lee HC, Park BL, Kim H, Jang MJ, Han YM, et al. Epigenetic modification of retinoic acid-treated human embryonic stem cells. BMB Rep 2010;43:830-5.
27. Kim HJ, Lotan R. Identification of retinoid-modulated proteins in squamous carcinoma cells using high-throughput immunoblotting. Cancer Res 2004;64:2439-48.
28. Chen Y, Dokmanovic M, Stein WD, Ardecky RJ, Roninson IB. Agonist and antagonist of retinoic acid receptors cause similar changes in gene expression and induce senescence-like growth arrest in MCF-7 breast carcinoma cells. Cancer Res 2006;66:8749-61.
29. Wu J, Duan R, Cao H, Field D, Newnham CM, Koehler DR, et al. Regulation of epithelium-specific Ets-like factors ESE-1 and ESE-3 in airway epithelial cells: potential roles in airway inflammation. Cell Res 2008;18:649-63.
30. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
31. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the Claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
32. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5.
33. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
34. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-300.
35. Salvador MA, Wicinski J, Cabaud O, Toiron Y, Finetti P, Josselin E, et al. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Clin Cancer Res 2013;19:6520-31.
36. Oliver JR, Kushwah R, Hu J. Multiple roles of the epithelium-specific ETS transcription factor, ESE-1, in development and disease. Lab Invest 2012;92:320-30.